Search

Jared Kenneth Lunceford

age ~51

from Washington, UT

Get Report
Also known as:
  • Jared K Lunceford
  • Kenneth Charles Lunceford
  • Jared K Lanceford
  • Jared D
Phone and address:
1212 E High Ridge Dr, Washington, UT 84780
(801)6168592
Related to:
Connected to:

Jared Lunceford Phones & Addresses

  • 1212 E High Ridge Dr, Washington, UT 84780 • (801)6168592
  • 4087 Foothill Dr, Provo, UT 84604 • (801)6071462
  • 459 Stadium Ave, Provo, UT 84604 • (801)6071462
  • 3602 Riddle Ct, Bridgewater, NJ 08807 • (908)9279217
  • 362 Riddle Ct, Bridgewater, NJ 08807 • (609)9279217
  • 880 Buckingham Ct, Cary, NC 27511 • (919)4819998
  • Colorado Springs, CO
  • Evanston, WY
  • 3602 Riddle Ct, Bridgewater, NJ 08807 • (908)6125100

Work

  • Position:
    Machine Operators, Assemblers, and Inspectors Occupations

Education

  • Degree:
    Associate degree or higher

Us Patents

  • Blood-Based Biomarkers Of Tumor Sensitivity To Pd-1 Antagonists

    view source
  • US Patent:
    20180148790, May 31, 2018
  • Filed:
    Apr 12, 2016
  • Appl. No.:
    15/565233
  • Inventors:
    - Rahway NJ, US
    Jared Lunceford - Washington UT, US
    Andrey Loboda - Boston MA, US
    Terrill K. McClanahan - Sunnyvale CA, US
    Heather Hirsch - Brookline MA, US
  • Assignee:
    Merck Sharp & Dohme Corp. - Rahway NJ
  • International Classification:
    C12Q 1/6886
    G01N 33/566
    G01N 33/543
    G01N 33/574
    G01N 33/68
  • Abstract:
    The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

  • Gene Signature Biomarkers Of Tumor Response To Pd-1 Antagonists

    view source
  • US Patent:
    20160312295, Oct 27, 2016
  • Filed:
    Dec 15, 2014
  • Appl. No.:
    15/104000
  • Inventors:
    - Rahway NJ, US
    Andrey Loboda - Canton MA, US
    Jared Lunceford - Washington UT, US
    Terrill K. McClanahan - Sunnyvale CA, US
    Erin Murphy - Redwood City CA, US
    Robert H. Pierce - San Francisco CA, US
  • Assignee:
    Merck Sharp & Dohme Corp. - Rahway NJ
  • International Classification:
    C12Q 1/68
    C07K 16/28
    G06F 19/20
  • Abstract:
    The present disclosure describes gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

  • Pd-L1 Gene Signature Biomarkers Of Tumor Response To Pd-1 Antagonists

    view source
  • US Patent:
    20160312297, Oct 27, 2016
  • Filed:
    Dec 15, 2014
  • Appl. No.:
    15/104539
  • Inventors:
    - Rahway NJ, US
    Andrey Loboda - Canton MA, US
    Jared Lunceford - Washington UT, US
    Terrill K. McClanahan - Sunnyvale CA, US
    Erin Murphy - Redwood City CA, US
    Robert H. Pierce - San Francisco CA, US
  • Assignee:
    Merck Sharp & Dohme Corp. - Rahway NJ
  • International Classification:
    C12Q 1/68
    C07K 16/28
  • Abstract:
    The present disclosure describes PD-L1 gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

  • Ifn-Gamma Gene Signature Biomarkers Of Tumor Response To Pd-1 Antagonists

    view source
  • US Patent:
    20160304969, Oct 20, 2016
  • Filed:
    Dec 15, 2014
  • Appl. No.:
    15/104245
  • Inventors:
    - Rahway NJ, US
    Andrey Loboda - Canton MA, US
    Jared Lunceford - Washington UT, US
    Terrill K. McClanahan - Sunnyvale CA, US
    Erin Murphy - Redwood City CA, US
    Robert H. Pierce - San Francisco CA, US
  • Assignee:
    Merck Sharp & Dohme Corp. - Rahway NJ
  • International Classification:
    C12Q 1/68
    C07K 16/28
    G06F 19/20
  • Abstract:
    The present disclosure describes IFN-γ gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

Resumes

Jared Lunceford Photo 1

Distinguished Scientist

view source
Location:
Provo, UT
Industry:
Pharmaceuticals
Work:
Myriad Genetics 2007 - 2007
Associate Director of Biostatistics
Merck 2007 - 2007
Distinguished Scientist
Education:
North Carolina State University 1996 - 2001
Doctorates, Doctor of Philosophy, Statistics Brigham Young University 1994 - 1996
Master of Science, Masters, Molecular Biology Brigham Young University 1991 - 1994
Bachelors, Bachelor of Science, Molecular Biology
Skills:
Clinical Development
Pharmaceutical Industry
Oncology
Biostatistics
Therapeutic Areas
Translational Medicine
Fda
Validation
Genomics
Biomarker Discovery
Statistics
Jared Lunceford Photo 2

Jared Lunceford

view source

Youtube

Spring 2011 Morning Graduation at East Tennes...

Spring 2011 Morning Graduation at East Tennessee S...

The 10 AM May 7th, 2011 Graduation Ceremony for East Tennessee State U...

  • Category:
    Education
  • Uploaded:
    23 May, 2011
  • Duration:
    1h 52m 5s

Mylife

Jared Lunceford Photo 3

Jared Lunceford Provo UT

view source
You can find Jared Lunceford with our easy-to-use people finder tool. Get in touch with old friends and colleagues at MyLife.
Get Report for Jared Kenneth Lunceford from Washington, UT, age ~51
Control profile